<DOC>
	<DOCNO>NCT02231229</DOCNO>
	<brief_summary>French guideline currently recommend initiate 4-drug contain regimen associate isoniazid ( INH H ) , rifampicin ( RIFor RMP R ) , pyrazinamide ( PZA Z ) ethambutol ( EMB E ) pending result drug susceptibility test ( DST ) . The rationale behind routine use EMB prevent emergence resistance rifampicin ( RMP ) , case primary resistance INH . Hence , early detection resistance INH RIF use molecular test Mycobacterium tuberculosis could allow early adaptation antituberculosis treatment : ) start 3-drug contain regimen ( i.e . INH , RIF , PZA ) ; ii ) early enforcement treatment resistance suspect , pending depth susceptibility testing . duration treatment 6 month 12 month .</brief_summary>
	<brief_title>Rapid Detection Rifampin Isoniazid Resistance PCR Before Tuberculosis ( TB ) Treatment Initiation</brief_title>
	<detailed_description>The impact rapid detection resistance PCR poorly evaluate low-endemic country . In France , primary resistance isoniazid rifampicin estimate , respectively , 5.2 % , 1.2 % . Based estimate , French guideline currently recommend initiate 4-drug contain regimen associate isoniazid ( INH H ) , rifampicin ( RIFor RMP R ) , pyrazinamide ( PZA Z ) ethambutol ( EMB E ) pending result drug susceptibility test ( DST ) . The rationale behind routine use EMB prevent emergence resistance rifampicin ( RMP ) , case primary resistance INH . Hence , early detection resistance INH RIF use molecular test Mycobacterium tuberculosis could allow early adaptation antituberculosis treatment : ) start 3-drug contain regimen ( i.e . INH , RIF , PZA ) , patient fully susceptible isolates ( currently 95 % case ) ; ii ) early enforcement treatment resistance suspect , pending depth susceptibility testing . GenoType Â®MTB DR plus sensitivity RIF INH resistance detection estimate 100 % 83 % , respectively .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Pyrazinamide</mesh_term>
	<mesh_term>Ethambutol</mesh_term>
	<criteria>Adult patient active pulmonary tuberculosis ( TB ) positive respiratory sample microscopic examination acidfast bacillus ( AFB+ , ) eligible standard TB treatment 4 drug combination PCR ( Genotype MTBDR Plus v2.0 , Hain Lifescience ) result available within first 7 day tuberculosis treatment . seek care France ( metropolitan overseas ) accept followup 18 24 month inclusion . prior clinical examination Refusal participate study Prior history TB treatment For woman child bearing age , pregnancy , willing become pregnant breastfeeding Patient without healthcare insurance ( French social security ) Patient participate another clinical trial Any condition might compromise , investigator 's opinion , patient 's compliance protocol . Results culture available enrollment No HIV test available within last 3 month prior inclusion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Pulmonary tuberculosis</keyword>
	<keyword>Mycobacterium tuberculosis ( MTB )</keyword>
	<keyword>Drug Resistance ( DR )</keyword>
	<keyword>Isoniazid ( INH H )</keyword>
	<keyword>Rifampicin ( RIF RMP R )</keyword>
	<keyword>Pyrazinamide ( PZA Z )</keyword>
	<keyword>Ethambutol ( EMB E )</keyword>
	<keyword>Fast-TB</keyword>
	<keyword>Isoniazid , Rifampicin , Pyrazinamide ( HRZ )</keyword>
	<keyword>Isoniazid , Rifampicin , Pyrazinamide , Ethambutol ( HRZE )</keyword>
	<keyword>drug susceptibility test ( DST )</keyword>
	<keyword>Acid-Fast Bacilli ( AFB+ )</keyword>
	<keyword>Polymerase Chain Reaction ( PCR )</keyword>
</DOC>